Yingxin Pharmaceutical

Yingxin Pharmaceutical, also known as InnoSinn Pharma, is a clinical-stage biotechnology company based in Shanghai, China, focused on the discovery and development of innovative small molecule therapeutics for oncology. The company's research is primarily centered on the adenosine signaling pathway, which plays a critical role in tumor immune evasion. Its lead clinical asset, YX-2102, is a highly selective Adenosine A2A receptor (A2AR) antagonist currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. Yingxin is also advancing a pipeline of preclinical candidates, including inhibitors of Hematopoietic progenitor kinase 1 (HPK1), designed to enhance anti-tumor immunity. The company leverages its proprietary R&D platform to develop precision medicines that can be utilized as monotherapies or in combination with existing standard-of-care treatments.